Long-term safety of an experimental drug for Crohn's or colitis
Part of Digestive system clinical trials.
This study looks at the long-term safety and side effects of an investigational drug called balinatunfib in people with Crohn's disease or ulcerative colitis. It is for patients who have already completed a full year of treatment in a previous related study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease or ulcerative colitis.
- You have already completed 52 weeks (1 year) of treatment in either the SPECIFI-CD or SPECIFI-UC study.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
- You did not have to permanently stop taking the study drug in the earlier study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new drug called LMT503 in adults to learn its safety, tolerability, and how the body handles it. If you qualify, you may receive the study medicine in a controlled research setting with regular checkups and blood/heart monitoring.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.